As healthcare professionals, it is crucial to have an in-depth understanding of degenerative diseases such as Parkinson's. This article aims to provide a comprehensive overview of Parkinson's Disease, its etiology, pathophysiology, diagnosis, and treatment.
Parkinson's Disease (PD) is a chronic, progressive neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. The etiology is multifactorial, with genetic and environmental factors playing a role. The ensuing dopamine deficiency leads to the cardinal motor symptoms of PD: bradykinesia, rigidity, tremor, and postural instability.
Diagnosis of PD is primarily clinical, based on the presence of cardinal motor symptoms and response to dopaminergic therapy. Neuroimaging can aid in diagnosis but is not typically required. The UK Brain Bank criteria are commonly used, which require the presence of bradykinesia and at least one of either rigidity, 4-6Hz resting tremor, or postural instability.
Treatment of PD is symptomatic, aiming to improve quality of life by controlling symptoms. Pharmacological treatment primarily involves dopamine replacement with Levodopa, often combined with a dopa-decarboxylase inhibitor to increase its bioavailability. Other options include dopamine agonists, MAO-B inhibitors, and deep brain stimulation for refractory cases.
Parkinson's Disease is a progressive condition with a variable course. Non-motor symptoms, including cognitive impairment, psychiatric symptoms, and autonomic dysfunction, often become more prominent as the disease progresses. Future research is focused on neuroprotective strategies and disease-modifying therapies.
In conclusion, Parkinson's Disease is a complex, multifaceted condition requiring a comprehensive and multidisciplinary approach. As healthcare professionals, it is our duty to stay abreast of the latest developments in order to provide the best possible care to our patients.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation